Company: CSTAF
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027555
Chunk: 88

Company: Constellation Acquisition Corp I
Filing Date: 2025-04-02
Form: 10-K
Item: Item 1
Chunk 88
---
 then-outstanding public shares. Our shareholders are not parties to,
or third-party beneficiaries of, this agreement and, as a result, will not have the ability to pursue remedies against our Sponsor, executive
officers, directors or director nominees for any breach of this agreement. As a result, in the event of a breach, our shareholders would
need to pursue a shareholder derivative action, subject to applicable law.

Our letter agreement with our Sponsor, officers and directors
may be amended without shareholder approval.

Our letter agreement with our Sponsor, affiliates of our Sponsor, officers
and directors contain provisions relating to transfer restrictions of our founder shares and private placement warrants, indemnification
of the Trust Account, waiver of redemption rights and participation in liquidating distributions from the Trust Account. The letter agreement
may be amended without shareholder approval. While we do not expect our board to approve any amendment to the letter agreement prior to
our Business Combination, it may be possible that our board, in exercising its business judgment and subject to its fiduciary duties,
chooses to approve one or more amendments to the letter agreement. Any such amendments to the letter agreement would not require approval
from our shareholders and may have an adverse effect on the value of an investment in our securities.

48

We may be unable to obtain additional financing to complete
our Business Combination or to fund the operations and growth of a target business, which could compel us to restructure or abandon a
particular Business Combination. If we are unable to complete our Business Combination, our public shareholders may receive only approximately
$10.00 per public share, or less in certain circumstances, on the liquidation of our Trust Account and our warrants will expire worthless.

Although we believe that the net proceeds of the IPO and the sale of
the private placement warrants will be sufficient to allow us to complete our Business Combination, because we have not yet selected any
prospective target business we cannot ascertain the capital requirements for any particular transaction. If the net proceeds of the IPO
and the sale of the private placement warrants prove to be insufficient, either because of the size of our Business Combination, the depletion
of the available net proceeds in search of a target business, the obligation to redeem for cash a significant number of shares from shareholders
who elect redemption in connection with our Business Combination or the terms of negotiated transactions to purchase shares in connection
with our Business Combination, we may be required to seek additional financing or to abandon the proposed Business Combination. Such financing
may not be available on acceptable terms